amyloidosis: A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
217 |
4. Check minimum number of eventsNone |
217 |
5. Include endpointsNone |
217 |
6. Filter based on genotype QC (FinnGen only) |
187 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E85
- Name in latin
- Amyloidosis in uno organo
Similar endpoints
↥List of similar endpoints to
Organ-limited amyloidosis
based on the number of shared cases.
Similar with more cases:
- Amyloidosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1581 | 719 | 850 |
| Only index persons | 1221 | 545 | 676 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 83.24 | 84.01 | 82.64 |
| Only index persons | 83.19 | 84.14 | 82.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 187 | 69 | 118 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 78.02 | 72.46 | 81.27 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 191
- Matched controls
- 1910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E85.4
ICD-10 Finland
Organ-limited amyloidosis
+∞
276.4
191
*
E85.9
ICD-10 Finland
Amyloidosis, unspecified
+∞
51.4
47
*
I43.1*E85.9
ICD-10 Finland
Cardiac amyloidosis
+∞
41.1
38
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.0
19.3
82
301
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.1
18.2
68
227
I50.9
ICD-10 Finland
Heart failure, unspecified
3.8
17.5
77
287
E85.89
ICD-10 Finland
Other amyloidosis
+∞
16.9
16
*
C03DA01
ATC
spironolactone; oral
4.4
16.7
51
146
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.8
16.4
33
66
I50.0
ICD-10 Finland
Congestive heart failure
4.4
15.8
48
136
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
14.9
128
708
C03CA01
ATC
furosemide; systemic
3.2
13.9
117
629
WX892
NOMESCO Finland
Monitored bed care
4.9
13.0
31
72
N08.4*E85.9
ICD-10 Finland
Glomerular disorders in amyloidosis
+∞
12.6
12
*
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
69.3
11.8
13
*
I43.1
ICD-10 Finland
Cardiomyopathy in metabolic diseases
+∞
11.6
11
*
FJA10
NOMESCO Finland
Transvenous biopsy of right ventricle
127.4
11.6
12
*
I61.1
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, cortical
37.5
11.4
14
*
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
5.8
10.9
21
40
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
10.8
41
134
I68.0*E85.9
ICD-10 Finland
Cerebral amyloid angiopathy
+∞
10.5
10
*
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.8
10.2
76
368
E85.3
ICD-10 Finland
Secondary systemic amyloidosis
+∞
9.4
9
*
I61.0
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, subcortical
13.4
9.0
15
12
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.8
9.0
56
245
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
4.6
8.2
20
47
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.6
8.1
63
306
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.8
8.1
19
43
I69.1
ICD-10 Finland
Sequelae of intracerebral haemorrhage
13.8
8.0
13
10
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
7.9
85
479
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.5
7.4
56
268
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
4.8
7.3
17
38
N08.4
ICD-10 Finland
Glomerular disorders in other endocrine, nutritional and metabolic diseases
+∞
7.3
7
*
C10AA01
ATC
simvastatin; oral
2.3
7.3
104
655
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
31.3
7.2
9
*
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.6
7.2
52
243
207
Kela drug reimbursment
Chronic arrhythmias
2.5
7.1
56
272
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
8.0
7.0
15
20
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
9.2
6.7
13
15
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.4
6.6
60
309
TFJ02
NOMESCO Finland
Muscle biopsy of heart
72.2
6.5
7
*
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.7
6.4
40
173
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.2
6.3
76
440
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
2.8
6.3
36
148
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
18.8
6.3
9
5
E85.0
ICD-10 Finland
Non-neuropathic heredofamilial amyloidosis
+∞
6.3
6
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.9
6.3
33
130
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.4
6.3
23
73
TFP20
NOMESCO Finland
Cardiodefibrillation
3.0
6.2
29
107
AA1AD
NOMESCO Finland
CT of head and brain
2.2
6.1
74
428
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
6.1
51
252
X59
ICD-10 Finland
Exposure to unspecified factor
2.6
6.1
40
177
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.0
6.1
18
49
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
59
43
19.41
66.95
5.4
2.0
1.21
1.53
ratio
0.95
37
21
59
46
18.11
64.46
5.8
2.4
59.73
34.10
mg/l
0.95
47
38
59
46
18.11
64.46
5.9
2.4
35.92
181.57
mg/l
0.54
47
37
34
63
6.35
18.35
4.6
1.4
0.63
0.34
g/l
0.43
27
52
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
40
6.40
13.07
3.7
2.4
0.31
0.32
iu/ml
0.06
13
23
110
591
3.03
12.76
7.1
3.3
4828.44
1657.19
ng/l
6.02
100
509
35
96
4.24
11.87
5.8
4.0
1.42
2.27
mmol/l
0.57
28
84
110
643
2.68
10.08
7.9
4.2
76.54
48.41
ng/l
1.20
96
507
115
704
2.59
9.33
9.1
4.1
33.31
34.36
g/l
0.97
107
651
54
231
2.86
9.02
2.6
1.9
29.69
29.71
s
0.01
54
220
30
91
3.72
8.78
1.7
2.4
1.33
1.61
g/l
0.84
23
86
125
812
2.56
8.71
16.1
5.7
1.20
1.21
mmol/l
0.63
113
678
115
728
2.46
8.34
14.2
5.5
1.20
1.21
mmol/l
0.04
110
651
63
305
2.59
8.18
2.1
1.9
—
—
—
0
0
31
101
3.47
8.14
8.7
3.2
161.08
95.03
ng/l
1.68
24
83
58
274
2.60
7.88
5.0
2.3
10.29
12.13
umol/l
1.22
53
248
122
813
2.39
7.60
11.0
9.3
4.84
4.28
e9/l
1.10
113
711
68
353
2.44
7.52
1.9
1.7
995.80
1170.89
nmol/l
0.97
47
270
69
367
2.38
7.18
4.6
2.6
415.06
360.23
umol/l
2.38
62
310
13
13
10.63
7.15
1.8
1.4
347.38
652.69
mg
0.29
13
13
90
548
2.21
6.70
5.1
3.4
—
—
—
0
0
37
150
2.82
6.69
7.0
3.4
2.14
1.95
mmol/l
0.12
32
126
9
5
18.79
6.32
1.1
1.0
—
—
—
0
0
17
45
4.05
5.96
3.4
2.1
117.55
123.00
g/l
0.36
11
39
19
55
3.73
5.90
1.5
1.2
—
—
—
0
0
14
23
6.48
5.81
1.2
1.5
3193.40
43334.23
e6/l
—
5
13
29
114
2.82
5.52
1.9
1.8
—
—
—
0
0
16
43
3.97
5.49
2.6
2.7
8.16
8.00
kpa
0.13
16
43
10
11
9.52
5.35
2.7
2.6
—
—
—
0
0
18
55
3.51
5.17
3.2
2.6
24.16
25.85
mmol/l
1.08
18
55
16
45
3.79
5.17
3.4
1.4
—
—
—
0
0
14
28
5.31
5.05
2.1
1.1
—
—
—
0
0
70
422
2.04
5.04
5.1
3.2
0.65
0.46
e6/l
0.38
57
313
15
33
4.84
4.99
2.9
1.2
0.21
0.23
g/l
0.28
15
33
73
451
2.00
4.89
2.6
2.2
3.21
3.19
mg/l
0.02
62
390
15
35
4.56
4.75
2.9
1.3
1.16
1.12
g/l
0.18
15
35
41
210
2.21
4.45
2.0
2.0
—
—
—
0
0
9
13
7.20
4.21
1.1
1.1
—
—
—
0
0
89
612
1.85
4.17
4.7
2.7
157.54
160.07
ug/l
0.04
80
547
18
64
3.00
4.08
1.8
1.6
—
—
—
0
0
14
45
3.28
3.73
1.9
1.4
—
—
—
0
0
41
225
2.05
3.71
1.9
1.9
—
—
—
0
0
91
657
1.74
3.44
3.4
3.2
—
—
estimate
—
0
0
9
18
5.19
3.41
4.7
1.7
11.91
6.80
pmol/l
—
9
18
158
1343
2.02
3.39
37.6
18.2
26.96
28.31
mg/l
0.23
145
1149
18
72
2.66
3.32
2.1
1.8
—
—
—
0
0
6
7
8.80
3.28
1.0
1.4
108.17
111.29
pmol/l
—
6
7
84
599
1.72
3.28
2.6
2.4
—
—
—
0
0
57
365
1.80
3.23
2.9
3.0
—
—
—
0
0
13
40
3.41
3.21
4.0
1.6
2.68
1.60
mg/l
1.89
13
32
74
513
1.72
3.18
3.6
3.7
35.05
8.53
mg/mmol
1.83
53
318
13
45
3.03
3.09
1.7
1.1
—
—
—
0
0
18
76
2.51
2.99
1.9
3.1
—
—
—
0
0
21
96
2.33
2.96
1.7
1.4
—
—
—
0
0
103
792
1.65
2.93
3.6
3.0
55.29
55.03
u/l
0.01
98
729
7
13
5.54
2.89
1.4
1.1
—
—
—
0
0
77
551
1.67
2.89
4.3
2.9
2.35
2.34
mmol/l
0.04
71
494
40
238
1.86
2.84
4.5
3.1
2.15
1.66
e6/l
0.13
20
126
36
207
1.91
2.83
9.9
6.8
1.04
1.30
mmol/l
0.15
31
165
163
1429
1.96
2.78
45.0
24.0
111.06
83.94
umol/l
4.62
157
1406
11
34
3.37
2.77
1.1
1.3
—
—
—
0
0
161
1410
1.90
2.70
44.6
21.5
138.95
139.74
mmol/l
2.58
155
1371
161
1410
1.90
2.70
45.5
21.6
4.02
4.02
mmol/l
0.07
155
1370
9
25
3.72
2.61
1.1
1.2
—
—
—
0
0
8
20
4.13
2.60
1.4
1.4
—
—
—
0
0
160
1405
1.86
2.57
16.9
12.1
22.51
23.40
u/l
0.51
152
1350
25
131
2.05
2.55
2.6
1.5
—
—
—
0
0
49
320
1.71
2.54
2.0
1.6
1.90
1.57
mg/l
0.29
35
251
14
57
2.57
2.51
1.4
1.9
—
—
—
0
0
53
357
1.67
2.45
2.7
3.0
2.49
2.45
mmol/l
1.00
45
318
5
8
6.38
2.38
1.2
1.4
103.80
116.13
%
—
5
8
162
1439
1.83
2.35
51.3
27.4
4.23
4.38
e12/l
2.88
154
1393
162
1439
1.83
2.35
51.3
27.4
235.07
236.64
e9/l
0.11
156
1403
28
158
1.90
2.33
5.7
3.8
—
—
—
0
0
93
729
1.54
2.24
2.3
2.1
86.55
96.14
pmol/l
1.15
58
382
40
257
1.70
2.19
4.1
3.0
0.43
1.14
e6/l
2.73
19
149
5
10
5.10
2.08
1.2
1.2
—
—
—
0
0
7
20
3.59
2.07
1.3
1.9
—
—
—
0
0
6
15
4.09
2.05
1.2
2.0
—
—
—
0
0
6
16
3.83
1.95
1.2
1.9
—
—
—
0
0
145
1277
1.56
1.87
5.9
6.8
41.28
40.06
mmol/mol
0.87
127
1163
54
391
1.53
1.81
2.6
3.3
0.67
0.88
ug/l
1.27
39
269
5
13
3.92
1.72
1.2
1.3
—
—
—
0
0
28
175
1.70
1.70
12.1
7.4
123.39
120.85
g/l
0.24
28
170
148
1321
1.53
1.68
5.2
5.9
2.40
2.57
mmol/l
1.32
131
1178
8
31
2.65
1.68
1.5
1.6
—
—
—
0
0
147
1313
1.52
1.63
5.1
5.6
5.92
6.06
mmol/l
0.88
132
1162
139
1230
1.48
1.60
4.8
5.0
2.31
2.03
mu/l
1.23
121
1085
7
26
2.75
1.59
1.7
1.5
—
—
—
0
0
6
20
3.06
1.59
2.7
3.1
—
—
—
0
0
34
228
1.60
1.58
12.9
5.9
103.68
104.42
mmol/l
0.43
34
228
5
15
3.39
1.53
1.2
1.3
0.22
0.22
nmol/l
—
5
9
5
15
3.39
1.53
1.4
1.2
—
—
—
0
0
32
214
1.60
1.51
1.3
1.3
37.35
42.14
iu/ml
0.09
11
67
23
141
1.72
1.50
7.8
3.4
1.20
1.22
mmol/l
0.58
23
118
19
110
1.81
1.49
16.5
9.1
94.73
93.77
%
0.48
19
110
16
90
1.85
1.38
17.3
8.5
15.64
15.69
%
0.02
16
84
92
771
1.37
1.35
4.5
4.1
0.00
1.86
estimate
0.50
27
161
137
1227
1.41
1.33
4.5
4.3
1.27
1.22
mmol/l
0.35
120
1086
6
24
2.55
1.31
1.0
1.1
—
—
—
0
0
10
48
2.14
1.30
1.3
1.5
—
—
—
0
0
8
35
2.34
1.28
1.4
1.3
—
—
—
0
0
8
35
2.34
1.28
1.4
1.3
—
—
—
0
0
28
189
1.56
1.28
13.8
7.9
—
—
—
0
0
67
538
1.38
1.27
3.9
5.0
20.78
22.08
%
0.33
33
291
113
996
1.33
1.12
3.8
4.0
15.12
15.15
pmol/l
0.03
100
881
5
21
2.42
1.09
1.4
1.2
—
—
—
0
0
141
1290
1.36
1.05
5.0
5.1
4.28
4.47
mmol/l
1.13
126
1165
7
34
2.10
1.04
1.1
1.5
—
—
—
0
0
9
47
1.96
1.03
1.3
1.5
—
—
—
0
0
79
673
1.30
0.96
5.1
6.1
3.56
5.18
ug/l
0.44
70
581
7
37
1.93
0.95
1.9
1.3
—
—
—
0
0
139
1281
1.31
0.90
4.9
5.0
1.39
1.46
mmol/l
1.03
123
1140
87
757
1.27
0.88
4.5
4.0
0.00
0.00
estimate
-0.00
28
163
27
200
1.41
0.82
1.3
1.3
3.78
17.44
u/ml
1.07
11
72
44
354
1.32
0.81
1.6
2.0
488.13
433.69
pmol/l
0.58
38
285
87
768
1.24
0.76
4.6
4.0
0.00
0.00
estimate
-0.00
29
169
7
40
1.78
0.72
1.1
1.5
—
—
—
0
0
5
26
1.95
0.71
1.4
1.3
—
—
—
0
0
7
44
1.61
0.66
1.1
1.4
—
—
—
0
0
27
211
1.33
0.61
3.1
4.9
34.50
32.24
%
0.51
16
139
71
626
1.21
0.60
2.4
2.2
81.10
79.23
nmol/l
0.19
63
538
6
37
1.64
0.56
1.2
1.4
—
—
—
0
0
137
1295
1.20
0.52
35.6
17.4
63.76
72.01
ml/min/173m2
3.55
126
1220
16
124
1.32
0.40
1.1
1.4
—
—
—
0
0
12
89
1.37
0.39
3.8
2.2
1.07
1.10
%
0.10
12
89
12
89
1.37
0.39
3.5
1.8
2.25
1.70
%
0.59
12
64
12
89
1.37
0.39
3.8
2.2
0.75
0.63
%
0.46
12
89
47
419
1.16
0.35
5.0
3.6
0.09
0.22
estimate
0.26
23
122
15
122
1.25
0.28
4.2
2.7
0.38
0.22
e6/l
0.49
15
116
30
339
0.86
0.26
4.3
4.5
1.01
1.02
kg/l
1.37
22
229
15
123
1.24
0.26
4.9
6.0
24.27
24.56
mmol/l
0.10
15
115
29
257
1.15
0.24
1.2
1.2
0.97
2.57
u/ml
—
6
58
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.8
—
—
—
0
0
9
108
0.83
0.13
2.0
1.4
—
—
—
0
0
5
45
1.11
0.10
2.8
1.1
—
—
—
0
0
48
461
1.06
0.08
4.9
4.2
0.05
0.00
estimate
0.48
20
141
54
523
1.05
0.07
1.8
1.7
22.39
20.86
nmol/l
0.24
46
425
12
116
1.04
0.00
1.9
1.4
—
—
—
0
0
59
589
1.00
0.00
5.0
4.2
0.08
0.01
estimate
0.36
26
137
0
8
0.00
-0.00
0.0
1.3
—
96.03
—
0
8
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
8.86
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
4.88
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint E4_AMYL_ORGAN and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_AMYL_ORGAN.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_AMYL_ORGAN – Organ-limited amyloidosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data